title: Effect of menopausal hormone therapy on components of the metabolic syndrome.
abstract: The world population is aging, and women will spend an increasing share of their lives in a postmenopausal state that predisposes to metabolic dysfunction. Thus, the prevalence of metabolic syndrome (MetS) in women is likely to increase dramatically. This article summarizes the effects of menopause in predisposing to components of MetS including visceral obesity, dyslipidemia, type 2 diabetes (T2D) and hypertension (HTN). We also summarize the effects of menopausal hormone therapy (MHT) in reversing these metabolic alterations and discuss therapeutic advances of novel menopausal treatment on metabolic function.
authors.affiliation: Department of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, Orleans, LA, USA.
authors.forename: Dragana
authors.initials: D
authors.lastname: Lovre
authors.affiliation: Department of Pharmacology, School of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Sarah H
authors.initials: SH
authors.lastname: Lindsey
authors.affiliation: Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, 1430 Tulane Avenue SL-53, New Orleans, LA 70112, USA fmauvais@tulane.edu.
authors.forename: Franck
authors.initials: F
authors.lastname: Mauvais-Jarvis
keywords: adiposity; bazedoxifene; conjugated estrogen; diabetes; insulin resistance; menopausal hormone therapy; menopause; metabolic syndrome